RAPZ Raises Prices on Three Product Groups by an Average of 25%, Citing Raw Material, Wage and Overhead Costs

Daroei Rah Avard Tamin Pharmaceutical (ticker RAPZ) filed a group-A disclosure on Codal on 14 November 2026 (23 Aban 1405) saying its board has approved price increases on three product groups across some of their grades. The company says the rise averages 25 percent and is meant to cover higher raw material, wage and overhead costs.

The form lists a previous rate of 29,497,368 and a new rate of 36,826,316 (the unit is not given for either figure), which works out to an increase of about 24.9 percent. It also states that these products made up 51 percent of the company's total revenue in the previous fiscal year. The approval and effective date are both 14 November 2026, and the approving body is the board of directors.

RAPZ trades on Farabourse.